Trials / Completed
CompletedNCT04617028
Jaktinib Versus Hydroxycarbamide in Subjects With Intermediate-2 or High-risk Myelofibrosis
A Randomized, Double-blind, Double-simulated, Parallel-controlled, Multicenter Phase III Study Evaluating the Efficacy and Safety of Jaktinib Versus Hydroxycarbamide in Patients With Intermediate-2 or High-risk Myelofibrosis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 105 (actual)
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study is to determine the efficacy of Jaktinib versus Hydroxycarbamid in participants with Intermediate-2 or High-risk myelofibrosis
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Jaktinib | Jaktinib Hydrochloride Tablets administered orally twice daily |
| DRUG | Placebo to match Hydroxycarbamide | Placebo to match Hydroxycarbamide Tablets administered orally twice daily |
| DRUG | Hydroxycarbamide Tablets | Hydroxycarbamide Tablets administered orally twice daily |
| DRUG | Placebo to match Jaktinib | Placebo to match Jaktinib Tablets administered orally twice daily |
Timeline
- Start date
- 2021-02-05
- Primary completion
- 2023-10-18
- Completion
- 2023-10-18
- First posted
- 2020-11-05
- Last updated
- 2023-11-13
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04617028. Inclusion in this directory is not an endorsement.